Page 247 - Read Online

Martínez et al. Cardiomyocyte energetic changes in ischemia and arrythmogenesis

2012;448:43-53. O’Gorman E, Rück A, Brdiczka D. Some new aspects of creatine
35. Tate M, Grieve D, Ritchie R. Are targeted therapies for diabetic kinase (CK): compartmentation, structure, function and regulation for
cardiomyopathy on the horizon? Clin Sci 2017;131:897-915. cellular and mitochondrial bioenergetics and physiology. Biofactors
36. Bairwa S, Parajuli N, Dyck J. The role of AMPK in cardiomyocyte 1998;8:229-34.
health and survival. Biochim Biophys Acta 2016;1862:2199-210. 56. Weiss R, Gerstenblith G, Bottomley P. ATP flux through creatine
37. Vázquez-Carrera M. Unraveling the effects of PPARβ/δ on insulin kinase in the normal, stressed, and failing human heart. Proc Nat Acad
resistance and cardiovascular disease. Trends Endocrinol Metab Sci U S A 2005;102:808-13.
2016;27:319-34. 57. Fowler ED, Benoist D, Drinkhill MJ, Stones R, Helmes M, Wüst RC,
38. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley Stienen GJ, Steele DS, White E. Decreased creatine kinase is linked
WC.Myocardial fatty acid metabolism in health and disease. Physiol to diastolic dysfunction in rats with right heart failure induced by
Rev 2010;90:207-58. pulmonary artery hypertension. J Mol Cell Cardiol 2015;86:1-8.
39. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. 58. Bottomley PA, Panjrath GS, Lai S, Hirsch GA, Wu K, Najjar SS,
Circ Res 2004;95:568-78. Steinberg A, Gerstenblith G, Weiss RG. Metabolic rates of ATP
40. Barlaka E, Galatou E, Mellidis K, Ravingerova T, Lazou A. Role of transfer through creatine kinase (CK Flux) predict clinical heart
pleiotropic properties of peroxisome proliferator-activated receptors failure events and death. Sci Transl Med 2013;5:215re3.
in the heart: focus on the nonmetabolic effects in cardiac protection. 59. Kristjansson RP, Oddsson A, Helgason H, Sveinbjornsson G,
Cardiovasc Ther 2016;34:37-48. Arnadottir GA, Jensson BO, Jonasdottir A, Jonasdottir A, Bragi
41. Barlaka E, Ledvényiová V, Galatou E, Ferko M, Čarnická S, Walters G, Sulem G, Oskarsdottir A, Benonisdottir S, Davidsson
Ravingerová T, Lazou A. Delayed cardioprotective effects of WY- OB, Masson G, Magnusson OT, Holm H, Sigurdardottir O, Jonsdottir
14643 are associated with inhibition of MMP-2 and modulation I, Eyjolfsson GI, Olafsson I, Gudbjartsson DF, Thorsteinsdottir
of Bcl-2 family proteins through PPAR-α activation in rat hearts U, Sulem P, Stefansson K. Common and rare variants associating
subjected to global ischaemia-reperfusion. Can J Physiol Pharmacol with serum levels of creatine kinase and lactate dehydrogenase. Nat
2013;91:608-16. Commun 2016;7:10572.
42. Sun W, Liu Q, Leng J, Zheng Y, Li J. The role of pyruvate 60. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart
dehydrogenase complex in cardiovascular diseases. Life Sci failure. J Physiol 2003;555:1-13.
2015;121:97-103. 61. Kitzenberg D, Colgan SP, Glover LE. Creatine kinase in ischemic and
43. Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane inflammatory disorders. Clin Transl Med 2016;5:31.
transporters. Mol Asp Med 2013;34:121-38. 62. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W,
44. Deng D, Yan N. GLUT, SGLT, and SWEET: structural and Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial
mechanistic investigations of the glucose transporters. Protein Sci phosphocreatine-to-ATP ratio is a predictor of mortality in patients
2016;25:546-58. with dilated cardiomyopathy. Circulation 1997;96:2190-6.
45. Szablewski L. Glucose transporters in healthy heart and in cardiac 63. Nakae I, Mitsunami K, Omura T, Yabe T, Tsutamoto T, Matsuo
disease. Int J Cardiol 2017;230:70-5. S, Takahashi M, Morikawa S, Inubushi T, Nakamura Y, Kinoshita
46. Azevedo PS, Minicucci MF, Santos PP, Paiva SA, Zornoff LA. M, Horie M. Proton magnetic resonance spectroscopy can detect
Energy metabolism in cardiac remodeling and heart failure. Cardiol creatine depletion associated with the progression of heart failure in
Rev 2013;21:135-40. cardiomyopathy. J Am Coll Cardiol 2003;42:1587-93.
47. Lopaschuk GD. Metabolic modulators in heart disease: past, present, 64. Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an
and future. Can J Cardiol 2017;33:838-49. old hat. Am J Physiol Endocrinol Metab 2009;297:E578-91.
48. Fillmore N, Lopaschuk GD. Targeting mitochondrial oxidative 65. Fukushima A, Milner K, Gupta A, Lopaschuk GD. Myocardial energy
metabolism as an approach to treat heart failure. Biochim Biophys substrate metabolism in heart failure: from pathways to therapeutic
Acta 2013;1833:857-65. targets. Curr Pharm Des 2015;21:3654-64.
49. Luptak I, Yan J, Cui L, Jain M, Liao R, Tian R. Long-term effects 66. Aroor A, Mandavia C, Sowers J. Insulin resistance and heart failure:
of increased glucose entry on mouse hearts during normal aging and molecular mechanisms. Heart Fail Clin 2012;8:609-17.
ischemic stress. Circulation 2007;116:901-9. 67. Breckenridge RA, Piotrowska I, Ng KE, Ragan TJ, West JA, Kotecha
50. Liao R, Jain M, Cui L, D’Agostino J, Aiello F, Luptak I, Ngoy S, S, Towers N, Bennett M, Kienesberger PC, Smolenski RT, Siddall
Mortensen RM, Tian R. Cardiac-specific overexpression of GLUT1 HK, Offer JL, Mocanu MM, Yelon DM, Dyck JR, Griffin JL,
prevents the development of heart failure attributable to pressure Abramov AY, Gould AP, Mohun TJ. Hypoxic regulation of hand1
overload in mice. Circulation 2002;106:2125-31. controls the fetal-neonatal switch in cardiac metabolism. PLoS Biol
51. Domenighetti AA, Danes VR, Curl CL, Favaloro JM, Proietto J, 2013;11:e1001666.
Delbridge LM. Targeted GLUT-4 deficiency in the heart induces 68. Wende AR, Brahma MK, McGinnis GR, Young ME. Metabolic
cardiomyocyte hypertrophy and impaired contractility linked origins of heart failure. JACC Basic Transl Sci 2017;2:297-310.
with Ca(2+) and proton flux dysregulation. J Mol Cell Cardiol 69. Wende AR, Kim J, Holland WL, Wayment BE, O’Neill BT, Tuinei J,
2010;48:663-72. Brahma MK, Pepin ME, McCrory MA, Luptak I, Halade GV, Litwin
52. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in SE, Abel ED. Glucose transporter 4 (GLUT4) deficient hearts develop
heart failure. Circulation 2007;116:434-48. maladaptive hypertrophy in response to physiologic or pathologic
53. Varma N, Eberli FR, Apstein CS. Increased diastolic chamber stresses. Am J Physiol Heart Circ Physiol 2017;313:H1098-108.
stiffness during demand ischemia: response to quick length change 70. Wang J, Li Z, Wang Y, Zhang J, Zhao W, Fu M, Han X, Zhou J, Ge
differentiates rigor-activated from calcium-activated tension. J. Qiliqiangxin enhances cardiac glucose metabolism and improves
Circulation 2000;101:2185-92. diastolic function in spontaneously hypertensive rats. Evid Based
54. Guimarães-Ferreira L. Role of the phosphocreatine system on Complement Alternat Med 2017;2017:3197320.
energetic homeostasis in skeletal and cardiac muscles. Einstein 71. Korvald C, Elvenes OP, Myrmel T.Myocardial substrate metabolism
2014;12:126-31. influences left ventricular energetics in vivo. Am J Physiol Heart Circ
55. Wallimann T, Dolder M, Schlattner U, Eder M, Hornemann T, Physiol 2000;278:H1345-51.

Vessel Plus ¦ Volume 1 ¦ December 28, 2017 239